This Dutch Drugmaker’s Stock Jumps 38%. Here’s Why.
1. Genmab to acquire Merus for approximately $8 billion in cash. 2. Acquisition includes access to petosemtamab, targeting head and neck cancer. 3. Petosemtamab projected to generate $1 billion annual revenue by 2029. 4. Deal expected to close early in Q1 2026, with initial drug launch in 2027. 5. Genmab stock dropped 4.1% post-announcement, while Merus shares surged 38%.